Immunomedics

Esmo 2020 preview – late-breaking immunotherapy
Esmo 2020 preview – late-breaking immunotherapy
EP Vantage
ESMO
immunotherapy
Big Pharma
Merck
Bristol-Meyers Squibb
cancer
Immunomedics
Roche
Flag link:
Gilead to buy cancer drugmaker Immunomedics for $21B
Gilead to buy cancer drugmaker Immunomedics for $21B
BioPharma Dive
Gilead Sciences
M&A
cancer
Immunomedics
Flag link:
OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020
OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020
Beckers Hospital Review
OptumRx
Roche
PTC Therapeutics
risdiplam
SMA
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Immunomedics
Trodelvy
triple negative breast cancer
Flag link:
Immunomedics Says Harout Semerjian Decided To Step Down From Role As President And CEO
Immunomedics Says Harout Semerjian Decided To Step Down From Role As President And CEO
Reuters
Immunomedics
Pharma CEOs
Harout Semerjian
Flag link:
Immunomedics raises $459M as Trodelvy breast cancer launch kicks off amid COVID-19
Immunomedics raises $459M as Trodelvy breast cancer launch kicks off amid COVID-19
Fierce Pharma
Immunomedics
drug launches
Trodelvy
triple-negative breast cancer
pandemic
COVID-19
Flag link:
FDA Approves Immunomedics' Breast Cancer Drug
FDA Approves Immunomedics' Breast Cancer Drug
Motley Fool
FDA
Immunomedics
triple negative breast cancer
Trodelvy
Flag link:
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today
Motley Fool
Clovis Oncology
Immunomedics
Puma Biotechnology
cancer
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
These 3 Biotech Stocks Could Be Top Stocks in 2020
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Biomarin
Iovance
Immunomedics
Flag link:
Corporate and regulatory developments over the Christmas period
Corporate and regulatory developments over the Christmas period
EP Vantage
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Flag link:
Troubled Immunomedics tries again at FDA after rejection
Troubled Immunomedics tries again at FDA after rejection
Fierce Biotech
Immunomedics
IMMU-132
sacituzumab govitecan
FDA
metastatic triple-negative breast cancer
Flag link:
After FDA rejection, Immunomedics tries again with breast cancer drug
After FDA rejection, Immunomedics tries again with breast cancer drug
Biopharma Dive
Immunomedics
breast cancer
sacituzumab govitecan
metastatic triple-negative breast cancer
FDA
Flag link:
2 Biotechs With Approaching Drug Approvals
2 Biotechs With Approaching Drug Approvals
Motley Fool
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
These 6 biotech stocks are promising takeover targets
These 6 biotech stocks are promising takeover targets
Marketwatch
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Flag link:
With Immunomedics ADC deal, Everest bolsters cancer pipeline
With Immunomedics ADC deal, Everest bolsters cancer pipeline
BioCentury
Immunomedics
sacituzumab govitecan
Everest Medicines
Asia
Flag link:
Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Endpoints
Immunomedics
Michael Pehl
Flag link:
FDA uncovers data manipulation at Immunomedics plant making cancer drug
FDA uncovers data manipulation at Immunomedics plant making cancer drug
Fierce Pharma
FDS
Immunomedics
sacituzumab govitecan
drug manufacturing
Flag link:
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Biopharma Dive
Immunomedics
FDA
sacituzumab govitecan
Flag link:
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Immunomedics
FDA
breast cancer
sacituzumab govitecan
Flag link:

Pages